MoonLake Immunotherapeutics reported an insider sale by Kristian Reich involving the company’s Class A ordinary shares, par value $0.0001 per share. The transaction took place on July 20, 2026, and was reported on a Form 4 filed July 21, 2026. Reich sold 43,700 Class A ordinary shares at a weighted average price of $20.09 per share. The sale generated approximately $877,933 in gross proceeds before commissions, fees, or taxes. The filing indicates the shares were sold in multiple transactions at prices ranging from $20.00 to $20.25 per share. The transaction was reported as a sale under the Form 4 transaction code “S.” The filing states that the sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. Such plans allow insiders to set up prearranged trading instructions at a time when they are not in possession of material nonpublic information, providing a structured framework for later sales. An explanatory note says the shares are owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich may be deemed to beneficially own those shares indirectly, either through direct or indirect control, ownership, or position involving JeruCON Beratungsgesellschaft mbH. The provided filing text does not specify Reich’s remaining beneficial ownership after the sale. The form was signed on Reich’s behalf by Matthias Bodenstedt as attorney-in-fact on July 21, 2026.